Published in Hospital Law Weekly, March 1st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at CuraGen.
Report 1: CuraGen Corporation (CRGN) and TopoTarget A/S (TOPO) announced updated results from a Phase Ib trial of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors, along with three additional posters on PXD101, were presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held in Prague, Czech Republic.
Updated results were presented in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.